INTRODUCTION {#s1}
============

Early B-cell factor 3 (*EBF3*) is located on Chromosome 10q26.3 and is a member of the **c**ollier/olfactory-1/EBF (COE) family of transcription factors required for the development and differentiation of various cell types across species, from planarians to humans ([@TANAKAMCS002097C2]; [@TANAKAMCS002097C23]; [@TANAKAMCS002097C7]). The COE family of proteins has low sequence similarity to other protein families, but all COE proteins share a conserved amino-terminal DNA-binding domain with a unique zinc-finger binding motif, an immunogolubulin Ig-like, plexins, transcription factors (IPT/TIG) domain, and an atypical helix--loop--helix domain with a dimerization motif ([Fig. 1](#TANAKAMCS002097F1){ref-type="fig"}A; [@TANAKAMCS002097C18]; [@TANAKAMCS002097C23]). COE transcription factors play an important role in the nervous system and brain development, including neuronal differentiation, migration, axon guidance, and dendritogenesis, and are also necessary for the specification and maintenance of neuronal identity in adult neurons ([@TANAKAMCS002097C29]). Mice and humans have four COE paralogs, EBF1-4 ([@TANAKAMCS002097C9]), which may have complementary and redundant roles ([@TANAKAMCS002097C10]; [@TANAKAMCS002097C18]). Among the COE paralogs, *EBF3* is highly expressed throughout the brain during development in mice and humans ([@TANAKAMCS002097C30]; [@TANAKAMCS002097C26]) and is required for the migration of Cajal--Retzius cells during corticogenesis and the terminal differentiation and maintenance of specialized neurons in the adult brain ([@TANAKAMCS002097C10]; [@TANAKAMCS002097C14]; [@TANAKAMCS002097C27]; [@TANAKAMCS002097C4]). *EBF3* also acts as a putative tumor suppressor by activating cell cycle arrest and inducing apoptosis ([@TANAKAMCS002097C30]).

![(*A*) De novo variants in *EBF3*. Missense variants in EBF3 (NP_001005463.1) are shown *above* the protein diagram and likely gene-disrupting mutations are *below*. The variants identified in our patients are in black and ones in individuals reported by others are in gray. COE1, collier/olfactory-1/EBF. DBD, DNA-binding domain. IPT, Ig-like, plexins, transcription factors domain. HLHLH, atypical helix--loop--helix (HLH) domain. TAD, transactivation domain. Light blue region in COE1 DBD represents unique zinc finger binding motif. (*B*) Sequence alignment of EBF3 and its homologs across species with residues mutated in our patients in red. Macmu, rhesus monkey, Xentr, *Xenopus tropicalis*, Danre, zebrafish, Drome, *Drosophila melanogaster*, Tribr, parasitic roundworm.](TanakaMCS002097_F1){#TANAKAMCS002097F1}

Previous reports have identified approximately 100 patients with terminal 10q deletions, who demonstrate a wide range of clinical features frequently including delayed development, intellectual disability, and craniosynostosis ([@TANAKAMCS002097C11]). *EBF3* is within a shared deletion of Chromosome 10q26.3 in many of these patients. Four recent reports identified a total of 20 unrelated individuals and two siblings who have de novo variants in *EBF3* and a distinct neurodevelopmental syndrome ([@TANAKAMCS002097C1]; [@TANAKAMCS002097C3]; [@TANAKAMCS002097C15]; [@TANAKAMCS002097C24]). Here we add further evidence for the role of *EBF3* in brain development and expand the phenotype of this syndrome caused by pathogenic variants in *EBF3*. We describe seven unrelated individuals who have heterozygous de novo variants in *EBF3* that are predicted to be deleterious and who share common features of global developmental delay, intellectual disability (ID), hypotonia, and dysmorphic features.

RESULTS {#s2}
=======

Clinical WES was performed on 8057 individuals with developmental delay and/or intellectual disabilities in a single clinical laboratory. In 11 affected individuals from 11 unrelated families, we identified de novo variants in *EBF3* as potentially causative for the neurodevelopmental phenotype. Candidate disease-causing variants in the *EBF3* gene were confirmed by Sanger sequencing to be de novo. Only seven of the 11 de novo predicted pathogenic variants we observed are reported in the manuscript based on permission of the referring physicians to report the results. Some of the patients who were diagnosed were included in other publications and were therefore not included in this series. The variants include one nonsense, two frameshift deletions, one splice, and three missense variants ([Fig. 1](#TANAKAMCS002097F1){ref-type="fig"}). All seven variants identified are novel, located in highly evolutionarily conserved regions across species, and predicted to be deleterious by SIFT (<http://sift.jcvi.org/>), CADD (<http://cadd.gs.washington.edu/>), MetaSVM (<https://omictools.com/meta-svm-tool>), and MutationTaster (<http://www.mutationtaster.org/>) ([Table 1](#TANAKAMCS002097TB1){ref-type="table"}; [Fig. 1](#TANAKAMCS002097F1){ref-type="fig"}B). No likely gene-disrupting *EBF3* variants were detected in ExAC (<http://exac.broadinstitute.org/>), 1000 Genomes (<http://www.internationalgenome.org/>), ESP (<http://evs.gs.washington.edu/EVS/>), or our own internal database of 24,709 exomes of unaffected parents of children referred for testing. Additionally, the non-TCGA ExAC v0.3.1 gene tolerance scores of mis*Z* = 4.89 and *p*(LI) = 1.00 indicate that the gene is highly constrained against both missense and loss-of-function (LOF) variation across humans, respectively. Using TADA ([@TANAKAMCS002097C16]) default parameters for ID/DD and the expected mutation rate of 2.331847 × 10^−05^ for missense variants and 8.693607 × 10^−07^ for LOF variants ([@TANAKAMCS002097C21]), we calculate a false-discovery corrected *q*-value of 3.84 × 10^−08^ for observing six de novo LOF and five de novo missense variants in *EFB3* within our cohort.

###### 

Predicted pathogenicity and allele frequencies of *EBF3* variants

  Patient   Chromosome 10 coordinates (GRCh37/hg19)   Nucleotide change   Amino acid change   SIFT       PROVEAN              PolyPhen2                  Mutation-Taster             CADD Phred   Allele frequency in ExAC and GeneDx database of 49,418 alleles
  --------- ----------------------------------------- ------------------- ------------------- ---------- -------------------- -------------------------- --------------------------- ------------ ----------------------------------------------------------------
  1         131761731:T\>G                            c.191A\>C           K64T                Damaging   Deleterious (−4.3)   Probably damaging (0.99)   Disease-causing             19.3         0
  2         131761679:C\>-                            c.244delG           V82WfsX50           N/A        N/A                  N/A                        N/A                         N/A          0
  3         131757212:G\>T                            c.471C\>A           H157Q               Damaging   Deleterious (−6.2)   Possibly damaging (0.9)    Disease-causing             18.3         0
  4         131755591:C\>T                            c.486-1G\>A         IVS5-1G\>A          N/A        N/A                  N/A                        Disease-causing             32           0
  5         131676052:G\>A                            c.616C\>T           R206X               N/A        N/A                  N/A                        Automatic disease-causing   18.1         0
  6         131676042:C\>T                            c.626G\>A           R209Q               Damaging   Deleterious (−3.4)   Possibly damaging (0.9)    Disease-causing             20.4         0
  7         131639239GTACT GCTGGGGA\>-                c.1402_1414d eI13   T464PfsX10          N/A        N/A                  N/A                        N/A                         N/A          0

Clinical Presentation and Family History {#s2a}
----------------------------------------

The seven unrelated individuals include five females and two males who range in age from 1 to 24 yr (see [Table 2](#TANAKAMCS002097TB2){ref-type="table"}; [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002097/-/DC1)). They all share similar clinical features of global developmental delay or intellectual disabilities and of hypotonia or rarely hypertonia. Four of the five individuals over the age of three were verbal. Many of the individuals also demonstrated autism and/or attention deficit hyperactivity disorder (ADHD) and behavioral differences including poor eye contact, self-injurious behavior, or altered pain sensitivity. The only adult in our series also had tics and auditory and visual hallucinations. Notably, none had seizures nor were there consistent brain malformations, and head circumferences ranged from relatively small to relatively large. Most of the individuals have distinctive physical features including triangular face, synophrys, small ears, highly arched palate and crowded teeth, and single palmar crease ([Fig. 2](#TANAKAMCS002097F2){ref-type="fig"}). All of our patients have moderate-to-severe neurodevelopmental impairment. Approximately half of the patients have autism and half of them have motor coordination problems including ataxia. Six of the seven individuals had neurological findings, including coordination issues, insensitivity to pain, muscle weakness, and ataxic gait. Abnormal brain MRIs were observed, including vermis hypoplasia, delayed myelination, or irregular frontal cerebral white matter and protuberance of optic papillae in three separate patients ([Fig. 3](#TANAKAMCS002097F3){ref-type="fig"}). Additional notable features in the minority of individuals included altered pain sensitivity and sleep issues. Ophthalmologic problems were common and included strabismus, esotropia, amblyopia, and delayed visual maturation. Short stature was common and height was in the lower quartile for all but one individual. Skeletal abnormalities were less common and included pectus excavatum, severe scoliosis, pronation, and hallux valgus. Genitourinary issues included microphallus in two, urinary tract infections and hydronephrosis in one, and unilateral renal duplication, and vesicoureteral reflux in another.

![Photographs of patients with de novo variants in EBF3. (*A*) Patient 4 at 11 yr old. Note triangular face. (*B,B*′) Patient 5 at 11 yr old. Note round, mildly coarse face, mild maxillary hypoplasia and prominent mandible, highly arched eyebrows and synophrys, long palpebral fissures, short philtrum and thin upper lip, and anteverted nares.](TanakaMCS002097_F2){#TANAKAMCS002097F2}

![Brain imaging data of individual with EBF3 variant. (*A*,*B*) Sagittal and (*A*′,*B*′) axial images of Individual 4 at 9 mo (*A*,*A*′) and 9 yr (*B*,*B*′) of age show a mild hypoplasia of the cerebellar vermis, mildly dysplastic corpus callosum, and small pericallosal lipoma without evidence of significant progression.](TanakaMCS002097_F3){#TANAKAMCS002097F3}

DISCUSSION {#s3}
==========

We add to the emerging evidence for a clinical syndrome characterized by global developmental delay/intellectual disability, autism, hypotonia, and dysmorphic features due to heterozygous de novo predicted pathogenic variants in *EBF3*. Although not observed in all patients, ataxia/coordination problems, strabismus, skeletal abnormalities, short stature, and urogenital anomalies are also common features. The allelic spectrum we observed includes several likely gene-disrupting variants: one nonsense, two frameshift, and one splice variant. In addition there are three de novo missense variants, (p.(Lys64Thr), p.(His157Gln), and p.(Arg209Gln), which are all in the COE1 DNA-binding domain (DBD) ([Fig. 4](#TANAKAMCS002097F4){ref-type="fig"}; [@TANAKAMCS002097C23]). The p.(His157Gln) mutation lies in the "EBF zinc knuckle" motif located in the COE1 DBD, which is crucial for zinc coordination and positioning of residues for DNA binding. The splice site variant, c.486-1G\>A, may also cause the loss of the splice acceptor site and induce skipping of exon 6, which encodes the conserved zinc knuckle motif in the COE1 DBD. Molecular modeling of EBF3 mutations at the zinc knuckle has demonstrated decreased DNA affinity resulting in aberrant DNA binding ([@TANAKAMCS002097C1]). Altered expression or binding of *EBF3* is likely responsible for the predominance of neurological symptoms seen in our patients. Mutations in *Ebf3* in the brains of adult mice result in a modest reduction in olfactory bulb size and defective olfactory axon projections to the dorsal and lateral surfaces of the olfactory bulb ([@TANAKAMCS002097C29]). [@TANAKAMCS002097C17] further determined that *Ebf3* is strongly expressed in the midbrain, cerebellum, and the mantle layer of the spinal cord and generated *Ebf3*-deficient mice that died from respiratory failure due to dysfunctional diaphragm relaxation within 12 h following birth (P0.5) ([@TANAKAMCS002097C17]). Detailed investigation of the brains of *Ebf3* mutant mice and the generation of conditional knockout mice will likely reveal additional functions for *EBF3* in regulating the genetic programs involved in developing and maintaining neuronal function. In humans, reports of deletions of a common 1-Mb region on 10q26.3 including *EBF3* have been associated with severe neurodevelopmental delay and intellectual disability ([@TANAKAMCS002097C11]), although additional genes in the interval including *MGMT*, *PPP2R2D*, and *BNIP3* may also contribute to the phenotype in 10q26.3 deletion patients.

![Deleterious de novo missense variants in the EBF DNA-binding domain (DBD). (*A*) Structural representation of the EBF DBD based on original 3D representation of EBF3 in [@TANAKAMCS002097C23] with the three residues affected by missense variants in our patients in green. The H157 residue is part of the EBF zinc knuckle (box), which coordinates EBF binding to DNA. (*B*) Top view of residues involved in zinc coordination are indicated.](TanakaMCS002097_F4){#TANAKAMCS002097F4}

Four groups independently reported a total of 22 unique individuals who have *EBF3* nonsense, missense, and splice variants with clinical features shared by our patients ([@TANAKAMCS002097C1]; [@TANAKAMCS002097C3]; [@TANAKAMCS002097C15]; [@TANAKAMCS002097C24]), including one individual with a diagnosis of ADHD ([@TANAKAMCS002097C15]), three with autistic-like behavior ([@TANAKAMCS002097C24]), and one with a family history of ADHD and sleep problems ([@TANAKAMCS002097C1]). Several of our patients exhibited behavioral differences including repetitive hair pulling, self-injurious face rubbing, and lack of eye contact or social smile. Three of the individuals with autism in our study also had abnormal brain imaging, including vermis hypoplasia, delayed myelination, and small structural defects in the right temporal lobe (Patient 5) and optic papillae (Patient 6) ([Table 2](#TANAKAMCS002097TB2){ref-type="table"}; [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002097/-/DC1)). We provide additional evidence for the role of *EBF3* in brain development and hypothesize that decreased or aberrant binding of EBF3 to its targets lead to abnormal gene regulation during brain development and may be responsible for the global developmental delay and altered brain function consistently observed in individuals with mutations in *EBF3*. We suggest the variants we describe result in loss of function and haploinsufficiency of EBF3 and are a cause of autism and intellectual disabilities.

###### 

Clinical details of patients with *EBF3* variants

  Patient   Age     Sex   Variant                              Age at sitting   Age at walking                                      Verbal skills                                                             Muscle tone          Additional neurological findings                                                                                                             Vision                            Seizure   Abnormal behavior                                                                                                            ADD/ADHD        Brain MRI                                                                                                               Renal or urogenital issues                                                                                                                                           Gl
  --------- ------- ----- ------------------------------------ ---------------- --------------------------------------------------- ------------------------------------------------------------------------- -------------------- -------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- --------- ---------------------------------------------------------------------------------------------------------------------------- --------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------
  1         30 mo   M     c.191A\>C p.Lys64Thr;                18 mo            Cannot walk on own, able to stand without support   Nonverbal; able to communicate with sign language                         Hypotonia            Coordination issues; insensitivity/decreased sensitivity to pain; fine and gross motor difficulties                                          N/A                               None      Moderate eye contact; did not smile until 11 mo old                                                                          N/A             N/A                                                                                                                     Small penis                                                                                                                                                          History of poor weight gain
  2         24 yo   F     c.244delG, p.Val82TrpfsX50           9 mo             2 yo                                                Talked at 9 mo; Full sentences, normal mild articulation problems         Hypotonia            None                                                                                                                                         Strabismus, surgically repaired   None      Autistic features; tics; hallucinations (auditory and visual); emotional fragility; self- injurious behavior; hair pulling   No              Normal                                                                                                                  Normal                                                                                                                                                               Normal
  3         10 yo   F     c.471C\>A, p.His157Gln               1 yo             3 yo                                                Talked at 5 yo; normal vocabulary for age with articulation differences   Hypotonia            Fine motor difficulties; decreased pain sensitivity                                                                                          Strabismus                        None      Autism; tantrums and melt-downs                                                                                              Hyperactivity   Normal                                                                                                                  Vesicostomy surgery for vesicoureteral reflux and poor bladder emptying; left renal duplication; urine retention with neurogenic bladder, needs nocturnal catheter   Normal
  4         11 yo   F     c.486-1G\>A, IVS5-1G\>A              N/A              Cannot walk on own, needs assistance or walker      Nonverbal, no words but hums tunes                                        Hypotonia            Muscle weakness; ataxic gait                                                                                                                 Strabismus, surgically repaired   None      Autistic features; rubs face on hard objects to point of bruising                                                            No              Vermis hypoplasia                                                                                                       Normal                                                                                                                                                               Constipation; requires G- tube feeds; takes only baby foods orally
  5         11 yo   F     c.616C\>T, p.Arg206X                 4 mo             14 mo; Wears leg braces                             Talked at 10 mo; Articulation defect                                      Hypotonia            Hyporeflexia or difficult to elicit DTRs; mild dysmetria and gait incoordination; inconsistent sensory exam, mild proximal muscle weakness   Refractive error                  None      Autism; oppositional defiant disorder                                                                                        ADHD            Small schizencephalic cleft in right temporal lobe and delayed myelination at 2 yo, later resolved                      History of UTIs and hydronephrosis, resolved with growth                                                                                                             Excess weight gain, BMI 33.5 (≫95th percentile)
  6         15 mo   M     c.626G\>A p.Arg209Gln                9 mo             Cannot walk at 12 mo                                Babbling at 8 mo; No clear first words at 12 mo                           Hypotonia            Muscle weakness; ataxic gait                                                                                                                 Strabismus                        None      Some eye contact, but no social smile                                                                                        N/A             Curvilinear tract-like signal abnormality in left frontal cerebral white matter; protuberance of right optic papillae   Small penis; testes high in scrotum                                                                                                                                  Normal
  7         4 yo    F     c.1402_1414del13, p.Thr464ProfsX10   8 mo             2 yo                                                Talked at 2 yo; Speaking in full sentences at 4 yo                        Hypertonia in hips   Muscle weakness; ataxic gait                                                                                                                 Normal                            None      Oral fixation, awakens at night                                                                                              No              Normal                                                                                                                  Recurrent urinary tract infections                                                                                                                                   Normal

See [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002097/-/DC1) for additional details of clinical presentations.

yo, years old; ADD, attention deficit disorder; ADHD attention deficit hyperactivity disorder; N/A, not available.

The missense variants identified in the individuals in this study are all amino acid substitutions that result in a change in charge, which may alter the DNA binding of EBF3 to its binding partners, including aristaless related homeobox (*ARX*) ([@TANAKAMCS002097C12]; [@TANAKAMCS002097C20]). Genes regulated by ARX include ones that are involved in or have been linked to CNS disorders with intellectual disability and autism ([@TANAKAMCS002097C13]). *ARX* regulates the transcription of genes involved in cell differentiation, migration, and maturation during interneuron development in the brain and has been shown to repress *EBF3* and its putative tumor-suppressing properties, such as cell cycle arrest and apoptosis ([@TANAKAMCS002097C13]; [@TANAKAMCS002097C20]). *ARX* is predominantly expressed in the fetal and adult brain, testis, skeletal muscle, and pancreas ([@TANAKAMCS002097C22]; [@TANAKAMCS002097C28]). Patients with pathogenic variants in *ARX* exhibit heterogeneous clinical features resulting in a number of different developmental disorders including Ohtahara (OMIM ID: 308350), Partington (OMIM ID: 309510), and Proud (OMIM ID: 300004) syndromes, X-linked lissencephaly and ambiguous genitalia (XLAG; OMIM ID: 3000215), X-linked infantile spasms syndrome (ISSX; OMIM ID: 308350), and syndromic and nonsyndromic mental retardation ([@TANAKAMCS002097C22]; [@TANAKAMCS002097C19]).

The phenotypes and clinical outcomes of individuals with *ARX*-related disorders resemble those with mutations in *EBF3,* and disruptions in both genes are associated with intellectual disability with various neurological symptoms and are often associated with urogenital malformations. Recent reports of individuals with mutations in *EBF3* have documented genitourinary abnormalities, including several cases of undescended testes as well as micropenis and hypospadias ([@TANAKAMCS002097C1]; [@TANAKAMCS002097C3]; [@TANAKAMCS002097C15]; [@TANAKAMCS002097C24]). The male individuals in our study with missense variants, p.Lys64Thr (Patient 1) and p.Arg209Gln (Patient 6), each had a small penis and undescended testes perhaps because of aberrant binding of ARX to *EBF3*, which could result in the disruption of genitourinary patterning during development. It is thus possible that dysregulation of *EBF3* caused by defective binding by ARX may be part of the mechanism leading to the phenotype observed in these patients. Additional studies of *EBF3* are required to elucidate the molecular mechanisms of EBF3-associated neurodevelopmental deficiency and genitourinary abnormalities.

METHODS {#s4}
=======

Studies were approved by the Institutional Review Board of Columbia University.

Whole-Exome Sequencing (WES) {#s4a}
----------------------------

Genomic DNA was extracted from whole blood from the affected children and their parents. Exome sequencing at GeneDx was performed on exon targets captured using the Agilent SureSelect Human All Exon V4 (50 Mb) or the Clinical Research Exome kit (Agilent Technologies) according to the manufacturer\'s instructions. Libraries were sequenced using the Illumina HiSeq 2000 or 2500 sequencing system with 100-bp paired-end reads (Illumina). Whole-exome sequence data for all sequenced family members was analyzed using GeneDx\'s XomeAnalyzer (a variant annotation, filtering, and viewing interface for WES data) as described previously ([Table 3](#TANAKAMCS002097TB3){ref-type="table"}; [@TANAKAMCS002097C25]). Identified sequence variants of interest were confirmed in each proband and both parents by conventional di-deoxy DNA sequence analysis using an ABI3730 (Life Technologies).

###### 

Sequencing results

  Patient   WES 10× cov   Mean cov   Kit            EBF3 10× cov   EBF3 mean CDS cov
  --------- ------------- ---------- -------------- -------------- -------------------
  1         97.32%        153        Agilent CRE    100.00%        137
  2         92.88%        47         Agilent SSv4   96.77%         42
  3         96.36%        142        Agilent SSv4   100.00%        118
  4         91.52%        103        Agilent SSv4   100.00%        98
  5         97.00%        113        Agilent CRE    100.00%        101
  6         94.85%        113        Agilent CRE    100.00%        125
  7         94.69%        69         Agilent SSv4   98.03%         48
  Mean      94.95%        105        N/A            99.26%         95

Results from individuals identified at GeneDx. cov, coverage; CDS, coding sequence.

*EBF3* Primer Sequences {#s4b}
-----------------------

1.  Patient 1: Forward ACAGTGTCCAGGAACACGTGA, Reverse CAGGAGGTCTGACCAAGGGC

2.  Patient 2: Forward CATGTTTGGGATTCAGGAGAA, Reverse CCTGCCTCCCGCTTCTA

3.  Patient 3: Forward TAGCCCAGCTCCGAGGGTGA, Reverse CAATCGATGCCCTTCCCGGA

4.  Patient 4: Forward ACCGCTTCATTGTCAGACGT, Reverse TTTTGTTGCTGCTGCGGTTT (This primer set has been discontinued and is not recommended.)

5.  Patient 5: Forward TCTGATAACCCTAATAAATATCAT, Reverse GATTACTTCCTGAACAGTTGC

6.  Patient 6: Forward TCTGATAACCCTAATAAATATCAT, Reverse GATTACTTCCTGAACAGTTGC

7.  Patient 7: Forward GGCGCTAGAGCAGGTGGAAA, Reverse GAGATCACATCGGGCCCGTT

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Whole-exome sequencing data are not publicly available because patient consent could not be obtained. The *EBF3* variants found in this study have been deposited in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar>/) under accession numbers SCV000584020.1--SCV000584025.1 and SCV000570295.2.
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